MS83, That could be a ruse. AMRN hired a guy that is experienced in
taking Cardiovascular drugs down the country by country approval path.
That buys time while (hopefully) a BO is being negotiated. I was glad
that JT DID NOT announce a JV for Europe of any kind as that leaves the
door for a BO open a bit wider.
It's hard to fathom how an amazing drug like Vascepa could see its
potential value for the US almost completely wiped away. Something
else to keep in mind. Perhaps AMRN will have a better version of
Vascepa such as a one-a-day that Mochida is working on. Perhaps such
a new version, once developed and sold as a new branded drug could
be priced (in the US) to undercut generics. BP could use the Vascepa
that was geared toward the US to repurpose for Europe and ROW. The
"new" branded version of Vascepa could be launched by BP with appropriate
DTC advertising to make generic Vascepa meaningless. Because generics
cannot advertise, the US market would belong to the New, improved,
BP Branded and promoted one a day version! Hopefully, patents for it
would provide exclusivity beyond the "old" Vascepa expiration.
If the above idea is viable it may be a way for a BP acquirer of AMRN
to ultimately dominate the US Omega-3 market...after dominating Europe.
News 
Market Data 
Discover 
